학술논문
Antibodies as drugs—a Keystone Symposia report.
Document Type
Article
Author
Cable, Jennifer; Saphire, Erica Ollmann; Hayday, Adrian C.; Wiltshire, Timothy D.; Mousa, Jarrod J.; Humphreys, David P.; Breij, Esther C. W.; Bruhns, Pierre; Broketa, Matteo; Furuya, Genta; Hauser, Blake M.; Mahévas, Matthieu; Carfi, Andrea; Cantaert, Tineke; Kwong, Peter D.; Tripathi, Prabhanshu; Davis, Jonathan H.; Brewis, Neil; Keyt, Bruce A.; Fennemann, Felix L.
Source
Subject
*BISPECIFIC antibodies
*MONOCLONAL antibodies
*DEEP learning
*CONFERENCES & conventions
*AUTOIMMUNE diseases
*DISEASE progression
*IMMUNOGLOBULINS
*
*
*
*
*
*
Language
ISSN
0077-8923
Abstract
Therapeutic antibodies have broad indications across diverse disease states, such as oncology, autoimmune diseases, and infectious diseases. New research continues to identify antibodies with therapeutic potential as well as methods to improve upon endogenous antibodies and to design antibodies de novo. On April 27–30, 2022, experts in antibody research across academia and industry met for the Keystone symposium "Antibodies as Drugs" to present the state‐of‐the‐art in antibody therapeutics, repertoires and deep learning, bispecific antibodies, and engineering. [ABSTRACT FROM AUTHOR]